Perspective Therapeutics (CATX) Current Assets (2011 - 2026)
Perspective Therapeutics (CATX) posted Current Assets of $275.4 million for Q1 2026, up 85.56% sequentially from $148.4 million in Q4 2025, and up 27.63% YoY from $215.7 million in Q1 2025.
Perspective Therapeutics (CATX) Current Assets (2011 - 2026) Analysis & Trends
Perspective Therapeutics has reported Current Assets for 16 years, with the latest figure at $275.4 million in Q1 2026.
- Quarterly Current Assets rose 27.63% year-over-year to $275.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $275.4 million (up 27.63% YoY) and the FY2025 annual result came in at $148.4 million, down 35.81% from the prior year.
- Current Assets advanced to $275.4 million in Q1 2026 per CATX's latest filing, from $148.4 million in the prior quarter.
- Over five years, Current Assets peaked at $294.2 million in Q2 2024 and troughed at $16.8 million in Q4 2023.
- A 5-year average of $137.7 million and a median of $148.4 million in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2024: Current Assets plunged 68.36% in 2023, then surged 1272.93% in 2024.
- Over 5 years, Current Assets stood at $53.2 million in 2022, then slumped by 68.36% to $16.8 million in 2023, then soared by 1272.93% to $231.2 million in 2024, then slumped by 35.81% to $148.4 million in 2025, then soared by 85.56% to $275.4 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $275.4 million, $148.4 million, and $178.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.19 Bn | 194.59 Bn | 7.27 Bn | 24.52 Bn |
| 2 | Stryker | 129.95 Bn | 126.47 Bn | 4.50 Bn | 14.42 Bn |
| 3 | Medtronic | 120.06 Bn | 110.84 Bn | 6.41 Bn | 24.79 Bn |
| 4 | Boston Scientific | 74.14 Bn | 73.60 Bn | 3.85 Bn | 7.97 Bn |
| 5 | Edwards Lifesciences | 52.74 Bn | 48.49 Bn | 1.35 Bn | 6.82 Bn |
| 6 | Dexcom | 34.60 Bn | 32.65 Bn | 830.00 Mn | 4.09 Bn |
| 7 | GE HealthCare Technologies | 34.20 Bn | 32.10 Bn | 2.18 Bn | 10.50 Bn |
| 8 | Koninklijke Philips | 26.46 Bn | 23.13 Bn | 4.55 Bn | 10.84 Bn |
| 9 | Steris | 23.25 Bn | 22.77 Bn | 684.20 Mn | 2.45 Bn |
| 10 | Perspective Therapeutics | 388.50 Mn | 388.50 Mn | - | 241.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 241.52 Mn |
| Mar 31, 2026 | 275.35 Mn |
| Dec 31, 2025 | 148.39 Mn |
| Sep 30, 2025 | 178.50 Mn |
| Jun 30, 2025 | 195.96 Mn |
| Mar 31, 2025 | 215.74 Mn |
| Dec 31, 2024 | 231.16 Mn |
| Sep 30, 2024 | 270.17 Mn |
| Jun 30, 2024 | 294.24 Mn |
| Mar 31, 2024 | 188.20 Mn |
| Dec 31, 2023 | 16.84 Mn |
| Sep 30, 2023 | 21.69 Mn |
| Jun 30, 2023 | 31.95 Mn |
| Mar 31, 2023 | 40.27 Mn |
| Dec 31, 2022 | 53.22 Mn |
| Sep 30, 2022 | 57.54 Mn |
| Jun 30, 2022 | 59.33 Mn |
| Mar 31, 2022 | 62.76 Mn |
| Dec 31, 2021 | 63.60 Mn |
| Sep 30, 2021 | 64.96 Mn |